AU2013219935B2 - Long-acting coagulation factors and methods of producing same - Google Patents

Long-acting coagulation factors and methods of producing same Download PDF

Info

Publication number
AU2013219935B2
AU2013219935B2 AU2013219935A AU2013219935A AU2013219935B2 AU 2013219935 B2 AU2013219935 B2 AU 2013219935B2 AU 2013219935 A AU2013219935 A AU 2013219935A AU 2013219935 A AU2013219935 A AU 2013219935A AU 2013219935 B2 AU2013219935 B2 AU 2013219935B2
Authority
AU
Australia
Prior art keywords
ctp
coagulation factor
another embodiment
polypeptide
fix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013219935A
Other languages
English (en)
Other versions
AU2013219935A1 (en
Inventor
Udi Eyal Fima
Gili Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48983616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013219935(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/372,540 external-priority patent/US8759292B2/en
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of AU2013219935A1 publication Critical patent/AU2013219935A1/en
Application granted granted Critical
Publication of AU2013219935B2 publication Critical patent/AU2013219935B2/en
Priority to AU2016202829A priority Critical patent/AU2016202829B2/en
Priority to AU2017219044A priority patent/AU2017219044B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Glass Compositions (AREA)
AU2013219935A 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same Active AU2013219935B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016202829A AU2016202829B2 (en) 2012-02-14 2016-05-03 Long-acting coagulation factors and methods of producing same
AU2017219044A AU2017219044B2 (en) 2012-02-14 2017-08-24 Long-acting coagulation factors and methods of producing same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/372,540 2012-02-14
US13/372,540 US8759292B2 (en) 2006-02-03 2012-02-14 Long-acting coagulation factors and methods of producing same
PCT/IL2013/050107 WO2013121416A1 (en) 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202829A Division AU2016202829B2 (en) 2012-02-14 2016-05-03 Long-acting coagulation factors and methods of producing same

Publications (2)

Publication Number Publication Date
AU2013219935A1 AU2013219935A1 (en) 2014-09-25
AU2013219935B2 true AU2013219935B2 (en) 2016-02-04

Family

ID=48983616

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013219935A Active AU2013219935B2 (en) 2012-02-14 2013-02-05 Long-acting coagulation factors and methods of producing same
AU2016202829A Active AU2016202829B2 (en) 2012-02-14 2016-05-03 Long-acting coagulation factors and methods of producing same
AU2017219044A Active AU2017219044B2 (en) 2012-02-14 2017-08-24 Long-acting coagulation factors and methods of producing same

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016202829A Active AU2016202829B2 (en) 2012-02-14 2016-05-03 Long-acting coagulation factors and methods of producing same
AU2017219044A Active AU2017219044B2 (en) 2012-02-14 2017-08-24 Long-acting coagulation factors and methods of producing same

Country Status (22)

Country Link
EP (4) EP3791890B1 (enExample)
JP (2) JP6242819B2 (enExample)
KR (3) KR102310704B1 (enExample)
CN (2) CN104427994A (enExample)
AU (3) AU2013219935B2 (enExample)
BR (1) BR122021004014B1 (enExample)
CA (1) CA2870621C (enExample)
CL (2) CL2014002183A1 (enExample)
CO (1) CO7131365A2 (enExample)
DK (2) DK3326642T3 (enExample)
EA (2) EA201790960A3 (enExample)
ES (3) ES2665319T3 (enExample)
HU (1) HUE053068T2 (enExample)
IL (2) IL264959B (enExample)
MX (3) MX362446B (enExample)
MY (1) MY172539A (enExample)
NO (1) NO2920022T3 (enExample)
PE (1) PE20142290A1 (enExample)
PL (2) PL3326642T3 (enExample)
PT (1) PT3791890T (enExample)
SG (1) SG11201404836QA (enExample)
WO (1) WO2013121416A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2013219935B2 (en) 2012-02-14 2016-02-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
KR102172937B1 (ko) * 2015-06-19 2020-11-03 옵코 바이오로직스 리미티드 장기-작용성 응고 인자 및 그의 제조 방법
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
BR112019000610A2 (pt) * 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US20100317585A1 (en) * 2006-02-03 2010-12-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same
US20120208759A1 (en) * 2006-02-03 2012-08-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
DK0461200T3 (da) 1989-02-21 1997-03-10 Univ Washington Modificerede former af reproduktionshormoner
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CN1245510C (zh) * 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
TWI538916B (zh) * 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
CN102112157B (zh) * 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
AU2013219935B2 (en) * 2012-02-14 2016-02-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
KR102341581B1 (ko) * 2012-11-20 2021-12-21 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792460A (en) * 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
US20100317585A1 (en) * 2006-02-03 2010-12-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same
US20120208759A1 (en) * 2006-02-03 2012-08-16 Udi Eyal Fima Long-acting coagulation factors and methods of producing same

Also Published As

Publication number Publication date
KR102310704B1 (ko) 2021-10-08
MX393997B (es) 2025-03-24
PT3791890T (pt) 2025-02-14
BR112014020198A2 (pt) 2018-05-15
EA028578B1 (ru) 2017-12-29
KR102118729B1 (ko) 2020-06-05
EP2822576A1 (en) 2015-01-14
EP4488289A3 (en) 2025-03-19
KR20200063274A (ko) 2020-06-04
JP6510002B2 (ja) 2019-05-08
KR20210125595A (ko) 2021-10-18
EP3326642B1 (en) 2020-11-25
KR20140134673A (ko) 2014-11-24
JP2018065815A (ja) 2018-04-26
ES3010346T3 (en) 2025-04-02
BR122021004014B1 (pt) 2022-12-27
ES2665319T3 (es) 2018-04-25
AU2013219935A1 (en) 2014-09-25
JP2015508771A (ja) 2015-03-23
MX362446B (es) 2019-01-18
PL3791890T3 (pl) 2025-04-14
DK3326642T3 (da) 2021-02-22
CL2014002183A1 (es) 2015-01-09
SG11201404836QA (en) 2014-12-30
CN104427994A (zh) 2015-03-18
NO2920022T3 (enExample) 2018-06-09
CA2870621C (en) 2022-08-09
IL264959B (en) 2021-08-31
PE20142290A1 (es) 2015-01-15
ES2855133T3 (es) 2021-09-23
EA201491519A1 (ru) 2014-12-30
CL2017002233A1 (es) 2018-05-11
MX2019000708A (es) 2020-09-02
WO2013121416A1 (en) 2013-08-22
MY172539A (en) 2019-11-30
MX2014009910A (es) 2015-09-28
HK1205460A1 (en) 2015-12-18
AU2016202829B2 (en) 2017-05-25
AU2016202829A1 (en) 2016-05-19
EP3791890A1 (en) 2021-03-17
CO7131365A2 (es) 2014-12-01
EP3326642A1 (en) 2018-05-30
EA201790960A2 (ru) 2017-09-29
JP6242819B2 (ja) 2017-12-06
KR102630953B1 (ko) 2024-01-29
PL3326642T3 (pl) 2021-06-14
CA2870621A1 (en) 2013-08-22
EP2822576B1 (en) 2018-01-10
DK2822576T3 (en) 2018-04-16
HUE053068T2 (hu) 2021-06-28
EP4488289A2 (en) 2025-01-08
CN109535245A (zh) 2019-03-29
MX2022008807A (es) 2022-08-11
AU2017219044B2 (en) 2019-05-30
IL282121A (en) 2021-05-31
EP3791890B1 (en) 2024-11-13
EA201790960A3 (ru) 2018-01-31
IL282121B (en) 2022-06-01
EP2822576A4 (en) 2015-11-25
AU2017219044A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
US10144921B2 (en) Long-acting coagulation factors and methods of producing same
US8759292B2 (en) Long-acting coagulation factors and methods of producing same
AU2013219935B2 (en) Long-acting coagulation factors and methods of producing same
US11066658B2 (en) Long-acting coagulation factors and methods of producing same
AU2010269884B2 (en) Long-acting coagulation factors and methods of producing same
US10538755B2 (en) Long-acting coagulation factors and methods of producing same
IL288556B2 (en) Long-term coagulation factors and methods for their preparation
US12203113B2 (en) Long-acting coagulation factors and methods of producing same
HK40120325A (en) Long-acting coagulation factors and uses thereof
AU2017201513B2 (en) Long-acting coagulation factors and methods of producing same
HK1205460B (en) Long-acting coagulation factors and methods of producing same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)